866-997-4948(US-Canada Toll Free)

Preladenant Analysis and Estimates from 2014 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 34 Pages


GlobalDatas pharmaceuticals report, Preladenant Analysis and Estimates from 2014 to 2020 provides Preladenant sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of Preladenant including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Preladenant including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Preladenant in the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons Disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 8
2.9 GlobalData Report Guidance 8

3 Parkinsons Disease: Market Characterization 9
3.1 Parkinsons Disease Market 9
3.2 Parkinsons Disease Market Forecasts and CAGR 9
3.3 Factors Affecting Parkinsons Disease Market 10
3.3.1 High Prevalence: Parkinsons Disease is the Second Most Frequent Neurodegenerative Disorder 10
3.3.2 Increase in Old Age Population 10
3.3.3 Patent Expiry of Prominent Drugs 10

4 Stages of Parkinsons Disease and Comparison of Treatments 11
4.1 The Hoehn and Yahr Scale 11
4.2 Modified Hoehn and Yahr Scale 11
4.3 The UPDRS 12

5 Staging of Parkinsons Disease 15
5.1 Distribution of Parkinsons Disease Patients by Age Groups 15
5.2 Distribution of Patients by Stages 15

6 Preladenant 16
6.1 Introduction 16
6.2 Mechanism of Action 16
6.3 Clinical Studies 16
6.4 Status of Preladenant 17
6.5 Factors Affecting Sales of Preladenant 17
6.5.1 Used in Multiple Regimens 17
6.5.2 High intensity of Competition 17
6.5.3 Better efficacy 17
6.6 Drug Evaluation 18
6.6.1 Drug Risk Benefit Score 18
6.6.2 Intensity of Competition 19
6.7 Sales Forecasts 19
6.7.1 Target Patient Pool of Preladenant 19
6.7.2 Market Penetration 20
6.7.3 Dosing 20
6.7.4 Annual Cost of Therapy 20
6.7.5 Sales Estimates of Preladenant 21

7 Parkinson Disease Market: Appendix 30
7.1 Market Definitions 30
7.2 List of Abberiviations 30
7.3 Research Methodology 30
7.3.1 Coverage 30
7.3.2 Secondary Research 31
7.3.3 Forecasting 31
7.3.4 Number of Patients Approved to take the Drug 31
7.3.5 Net Penetration of Drug 31
7.3.6 Net Annual Dosing 32
7.3.7 Annual Cost of Therapy 33
7.3.8 Primary Research 33
7.3.9 Expert Panels 33
7.4 Drug Sales Estimates Model 33
7.5 Contact Us 33
7.6 Disclaimer 33
7.7 Sources 34

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 4: Four Items, Part 1 of UPDRS 12
Table 5: Thirteen Items, Part 2 of UPDRS 12
Table 6: Fourteen Items, Part 3 of UPDRS 13
Table 7: Fourteen Items, Part 3 of UPDRS 13
Table 8: Distribution of Parkinsons Patients According to Hoehn and Yahr Classification 15
Table 9: Status of Preladenant 17
Table 10: Drug Risk Benefit Score of Preladenant 18
Table 11: Efficacy Comparison of Preladenant 19
Table 12: Preladenant, Parkinsons Disease, Global, Sales Estimates ($m), 20142020 21
Table 13: Preladenant, Parkinsons Disease, The US, Sales Estimates ($m), 20142020 22
Table 14: Preladenant, Parkinsons Disease, The UK, Sales Estimates ($m), 20142020 23
Table 15: Preladenant, Parkinsons Disease, France, Sales Estimates ($m), 20142020 24
Table 16: Preladenant, Parkinsons Disease, Germany, Sales Estimates ($m), 20142020 25
Table 17: Preladenant, Parkinsons Disease, Italy, Sales Estimates ($m), 20142020 26
Table 18: Preladenant, Parkinsons Disease, Spain, Sales Estimates ($m), 20142020 27
Table 19: Preladenant, Parkinsons Disease, Japan, Sales Estimates ($m), 20172020 28

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 6
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 7
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 9
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 10
Figure 5: Points Distribution of UPDRS 14
Figure 6: Distribution of Parkinsons Disease Patients by Hoehn & Yahr Classification 15
Figure 7: Drug Model Diagram of Azilect in the US, EU and Japan 19
Figure 8: Preladenant, Parkinsons Disease, Global, Sales Estimates ($m), 20142020 21
Figure 9: Preladenant, Parkinsons Disease, The US, Sales Estimates ($m), 20142020 22
Figure 10: Preladenant, Parkinsons Disease, The UK, Sales Estimates ($m), 20142020 23
Figure 11: Preladenant, Parkinsons Disease, France, Sales Estimates ($m), 20142020 24
Figure 12: Preladenant, Parkinsons Disease, Germany, Sales Estimates ($m), 20142020 25
Figure 13: Preladenant, Parkinsons Disease, Italy, Sales Estimates ($m), 20142020 26
Figure 14: Preladenant, Parkinsons Disease, Spain, Sales Estimates ($m), 20142020 27
Figure 15: Preladenant, Parkinsons Disease, Japan, Sales Estimates ($m), 20172020 28
Figure 16: Preladenant, Parkinsons Disease, Sales Distribution by Country (%), 2020 29
Figure 17: Drug Model Diagram 32
Figure 18: Patients Approved for the Drug 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *